150,000 Shares in Kenvue Inc. $KVUE Bought by Slotnik Capital LLC

Slotnik Capital LLC bought a new stake in Kenvue Inc. (NYSE:KVUE) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 150,000 shares of the company’s stock, valued at approximately $2,588,000. Kenvue comprises approximately 0.6% of Slotnik Capital LLC’s investment portfolio, making the stock its 23rd biggest position.

Other large investors have also recently bought and sold shares of the company. Elyxium Wealth LLC bought a new position in Kenvue in the fourth quarter valued at about $26,000. Physician Wealth Advisors Inc. grew its stake in Kenvue by 67.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after purchasing an additional 618 shares during the period. SBI Securities Co. Ltd. grew its stake in Kenvue by 82.4% during the fourth quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock worth $39,000 after purchasing an additional 1,027 shares during the period. Leonteq Securities AG acquired a new stake in Kenvue in the fourth quarter valued at approximately $45,000. Finally, Quarry LP acquired a new stake in Kenvue in the fourth quarter valued at approximately $76,000. 97.64% of the stock is currently owned by institutional investors.

Kenvue Trading Up 0.6%

Shares of KVUE stock opened at $18.25 on Tuesday. The stock has a market capitalization of $35.03 billion, a PE ratio of 21.47, a P/E/G ratio of 1.38 and a beta of 0.54. Kenvue Inc. has a 1-year low of $14.02 and a 1-year high of $22.87. The business has a 50-day moving average of $17.45 and a 200 day moving average of $17.55. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.98 and a quick ratio of 0.70.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, May 7th. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.05. The company had revenue of $3.91 billion during the quarter, compared to analysts’ expectations of $3.84 billion. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.Kenvue’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.24 EPS. As a group, sell-side analysts anticipate that Kenvue Inc. will post 1.16 earnings per share for the current year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 13th were issued a $0.2075 dividend. The ex-dividend date was Wednesday, May 13th. This represents a $0.83 annualized dividend and a yield of 4.5%. Kenvue’s dividend payout ratio (DPR) is 97.65%.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on KVUE shares. Weiss Ratings cut Kenvue from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, May 29th. Argus upgraded Kenvue to a “hold” rating in a report on Friday, March 6th. Barclays lowered their target price on Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a research note on Tuesday, April 14th. UBS Group lowered their target price on Kenvue from $19.00 to $18.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 7th. Finally, Zacks Research upgraded Kenvue from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and twelve have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $19.33.

Insiders Place Their Bets

In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of the stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $17.66, for a total value of $679,751.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.59% of the company’s stock.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.